{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:08:28Z","timestamp":1793347708329,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40262-019-00804-x","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T08:03:56Z","timestamp":1563782636000},"page":"217-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8927","authenticated-orcid":false,"given":"Ken","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Newhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Dell\u2019Aringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalina","family":"Komashko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgul","family":"Kilavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sternas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelonitda","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-2683","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,22]]},"reference":[{"issue":"9","key":"804_CR1","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384\u201391. \nhttps:\/\/doi.org\/10.1172\/JCI80011\n\n.","journal-title":"J Clin Invest."},{"issue":"9","key":"804_CR2","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052\u201362. \nhttps:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0191\n\n.","journal-title":"Cancer Immunol Res."},{"key":"804_CR3","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA approved drug products. \nhttps:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/\n\n. Accessed 11 Feb 2019."},{"issue":"Suppl. 10","key":"804_CR4","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/jcph.990","volume":"57","author":"J Sheng","year":"2017","unstructured":"Sheng J, Srivastava S, Sanghavi K, Lu Z, Schmidt BJ, Bello A, et al. Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol. 2017;57(Suppl. 10):S26\u201342. \nhttps:\/\/doi.org\/10.1002\/jcph.990\n\n.","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"804_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):49\u201357. \nhttps:\/\/doi.org\/10.1002\/psp4.12139\n\n.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"1","key":"804_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):58\u201366. \nhttps:\/\/doi.org\/10.1002\/psp4.12143\n\n.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"4","key":"804_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cpt.982","volume":"103","author":"PG Baverel","year":"2018","unstructured":"Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631\u201342. \nhttps:\/\/doi.org\/10.1002\/cpt.982\n\n.","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"804_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","volume":"44","author":"H Li","year":"2017","unstructured":"Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, et al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017;44(5):403\u201314. \nhttps:\/\/doi.org\/10.1007\/s10928-017-9528-y\n\n.","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"5","key":"804_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cpt.656","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, Yu J, Li H, Liu J, Xu Y, Song P, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101(5):657\u201366. \nhttps:\/\/doi.org\/10.1002\/cpt.656\n\n.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"804_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/cpt.587","volume":"102","author":"M Stroh","year":"2017","unstructured":"Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017;102(2):305\u201312. \nhttps:\/\/doi.org\/10.1002\/cpt.587\n\n.","journal-title":"Clin Pharmacol Ther."},{"key":"804_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12406","author":"JJ Wilkins","year":"2019","unstructured":"Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S et al. Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in merkel cell carcinoma and urothelial carcinoma. CPT Pharmacometrics Syst Pharmacol. 2019. \nhttps:\/\/doi.org\/10.1002\/psp4.12406\n\n.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"3","key":"804_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcph.1324","volume":"59","author":"X Wang","year":"2019","unstructured":"Wang X, Ludwig EA, Passarell J, Bello A, Roy A, Hruska MW. Population pharmacokinetics and exposure-safety analyses of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma. J Clin Pharmacol. 2019;59(3):364\u201373. \nhttps:\/\/doi.org\/10.1002\/jcph.1324\n\n.","journal-title":"J Clin Pharmacol."},{"key":"804_CR13","doi-asserted-by":"publisher","unstructured":"Ogasawara K, Alexander GC. Use of population pharmacokinetic analyses among FDA-approved biologics. Clin Pharmacol Drug Dev. 2019. \nhttps:\/\/doi.org\/10.1002\/cpdd.658\n\n.","DOI":"10.1002\/cpdd.658"},{"issue":"15","key":"804_CR14","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2017.35.15_suppl.2568","volume":"35","author":"CY Jin","year":"2017","unstructured":"Jin CY, Zheng Y, Jin X, Mukhopadhyay P, Gupta A, Dennis PA, et al. Exposure-efficacy and safety analysis of durvalumab in patients with urothelial carcinoma (UC) and other solid tumors. J Clin Oncol. 2017;35(15):2568.","journal-title":"J Clin Oncol."},{"issue":"10","key":"804_CR15","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","volume":"194","author":"M Pyzik","year":"2015","unstructured":"Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol. 2015;194(10):4595\u2013603. \nhttps:\/\/doi.org\/10.4049\/jimmunol.1403014\n\n.","journal-title":"J Immunol."},{"issue":"6","key":"804_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/cpt.665","volume":"102","author":"JFM Jacobs","year":"2017","unstructured":"Jacobs JFM, Mould DR. The role of FcRn in the pharmacokinetics of biologics in patients with multiple myeloma. Clin Pharmacol Ther. 2017;102(6):903\u20134. \nhttps:\/\/doi.org\/10.1002\/cpt.665\n\n.","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"804_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cpt.779","volume":"102","author":"XS Xu","year":"2017","unstructured":"Xu XS, Schecter JM, Jansson R, Yan X. Response to \u201cThe role of FcRn in the pharmacokinetics of biologics in patients with multiple myeloma\u201d. Clin Pharmacol Ther. 2017;102(6):905. \nhttps:\/\/doi.org\/10.1002\/cpt.779\n\n.","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"804_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/cpt.577","volume":"101","author":"XS Xu","year":"2017","unstructured":"Xu XS, Yan X, Puchalski T, Lonial S, Lokhorst HM, Voorhees PM, et al. Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2017;101(6):721\u20134. \nhttps:\/\/doi.org\/10.1002\/cpt.577\n\n.","journal-title":"Clin Pharmacol Ther."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00804-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00804-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T23:36:06Z","timestamp":1595288166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00804-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,22]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00804-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,22]]},"assertion":[{"value":"22 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Celgene Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ken Ogasawara, Kathryn Newhall, Stephen E. Maxwell, Justine Dell\u2019Aringa, Vitalina Komashko, Nurgul Kilavuz, Richard Delarue, Myron Czuczman, Lars Sternas, Shelonitda Rose, C.L. Beach, Steven Novick, Simon Zhou, Maria Palmisano, and Yan Li are employees of Celgene Corporation and hold equity ownership in Celgene Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}